Universal newborn screening and adverse medical outcomes: A historical note

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 12, Issue 4, 2006, Pages 262-269

  Brosco, Jeffrey P ^a,b   Seider, Michael I ^a   Dunn, Angela C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Adverse events; History of medicine; Newborn screening

Indexed keywords

CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; GALACTOSEMIA; GENETIC DISORDER; HEALTH CARE COST; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; HUMAN GENOME PROJECT; LABORATORY DIAGNOSIS; MAPLE SYRUP URINE DISEASE; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; METABOLIC DISORDER; MORBIDITY; MORTALITY; NEWBORN; NEWBORN SCREENING; OUTCOMES RESEARCH; PHENYLKETONURIA; POPULATION RISK; PRIORITY JOURNAL; PUBLICATION; REVIEW; SICKLE CELL ANEMIA; UNITED STATES;

DIAGNOSTIC ERRORS; GENETIC SCREENING; HISTORY, 20TH CENTURY; HUMANS; INFANT, NEWBORN; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; PREDICTIVE VALUE OF TESTS; UNITED STATES;

EID: 33846023727     PISSN: 10804013     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/mrdd.20123     Document Type: Review

References (98)

1. 1996 U.S. Preventive Services Task Force. 1996. Guide to Clinical Preventive Services, 2nd ed. Washington, DC: US Department of Health and Human Services.
2. Alexander D. 1998. Prevention of mental retardation: Four decades of research. Ment Retard Dev Disabil Res Rev 4:50-58.
3. Aluoch JR. 1984. The treatment of sickle cell disease. A historical and chronological literature review of the therapies applied since 1910. Trop Geogr Med 36(4):S1-S26.
4. Bartter FC, Albright F, Forbes AP, et al. 1951. The effects of adrenocorticotropic hormone and cortisone in the adrenogenital syndrome associated with congenital adrenal hyperplasia: an attempt to explain and correct its disordered hormonal pattern. J Clin Invest 30: 237-251.
5. Berry HK, Wright S. 1967. Conference on treatment of phenylketonuria. J Pediatr 70:142-147.
6. Bessman SP. 1966. Legislation and advances in medical knowledge-acceleration or inhibition? J Pediaatr 69(2):334-338.
7. Beutler E, Baluda MC. 1966. A simple spot screening test for galactosemia. J Lab Clin Med 68:137-141.
8. Bickel H, Gerrard J, Hickmans EM. 1953. Influence of phenylalanine intake on phenylketonuria. Lancet 265:812, 813.
9. Bodegard G, Fyro K, Larsson A. 1983. Psychological reactions in 102 families with a newborn who has a falsely positive screening test for congenital hypothyroidism. Acta Paediatr Scand Suppl 304:1-21.
10. Botkin JR, Clayton EW, Fost NC, et al. 2006. Newborn screening technology: proceed with caution. Pediatrics 117:1793-1799.
11. Brandt AM. 1985. No Magic Bullet. New York: Oxford University Press.
12. Brosco JP. 1999. The early history of the infant mortality rate in America: a reflection upon the past and a prophecy of the future. Pediatrics 103:478-485.
13. Brosco JP, Mattingly M, Sanders LM. 2006. Impact of specific medical interventions on reducing the prevalence of mental retardation. Arch Pediatr Adolesc Med 160:302-309.
14. Butler G, Marrian G. 1937. Isolation of pregnane-3,17,20-triol from urine of women showing adrenogenital syndrome. J Biol Chem 119: 565-572.
15. Chase GA, Girves JP, Murphy EA. 1977. "Normal" children, "abnormal" results. Johns Hopkins Med J 140:1-7.
16. Clague A, Thomas A. 2002. Neonatal biochemical screening for disease. Clin Chim Acta 315:99-110.
17. Colgrove J. 2002. The McKeown thesis: a historical controversy and its enduring influence. Am J Clin Nutr 92:725-729.
18. Cranefield P. 1962. The discovery of cretinism. Bull Hist Med 36:489-511.
19. Decsi T, Kosztolanyi G, Czopf J. 1990. Sudden cortical blindness following transient enhancement of steroids administered in congenital adrenal hyperplasia (case report). Acta Paediatr Hung 30:107-110.
20. Dodge PR, Mancall E, Crawford JD, et al. 1959. Hypoglycemia complicating treatment of phenylketonuria with a phenylalanine-deficient diet: report of two cases. N Engl J Med 260:1104-1111.
21. Dussault JH. 1997. Screening for congenital hypothyroidism. Clin Obstet Gynecol 40:117-123.
22. Dussault JH. 1999. The anecdotal history of screening for congenital hypothyroidism. J Clin Endocrinol Metab 84:4332-4334.
23. Dussault JH, Coulombe C, Laberge C, et al. 1975. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr 86:670-674.
24. Feudtner JC. 2003. Bittersweet: Diabetes, Insulin, and the Transformation of Illness. Chapel Hill: The University of North Carolina Press.
25. Fisher DA, Dussault JH, Foley TP, et al. 1979. Screening for congenital hypothyroidism: results of screening one million North American infants. J Pediatr 94:700-705.
26. Fogelson MH. 1970. How to detect maple-syrup urine disease in newborn infants. Clin Pediatr (Phila) 9:538.
27. Fost N. 1999. Ethics of pediatric medicine. In: McMillan JA, DeAngelis CD, Feigin RD, Warshaw JB, editors. Oski's Pediatrics: principles and Practice. Philadelphia, PA: Lippincott Williams and Wilkins. pp 13-16.
28. Fost N. 2005. Session 1: Bioethics and American Children. The President's Council on Bioethics, Meeting on December 8-9, 2005. Washington, DC.
29. Fyro K, Bodegard G. 1987. Four-year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism. Acta Paediatr Scand 76:107-114.
30. Goppert F. 1917. Galaktosurie nach Milchzuckergabe bei angeborenem, familiaerem chronischem Leberleiden. Klin Wschr 54:473-477.
31. Guthrie R. 1968. Screening for inborn errors of metabolism in the newborn infant-a multiple test program. Birth Defects Orig Artic Ser 4:92-98.
32. Guthrie R. 1989. Newborn screening for sickle cell disease and other hemoglobinopathies. Newborn screening. Pediatrics 83(5, Part 2):836-838.
33. Guthrie R. 1992. The origin of newborn screening. Screening 1:5-15.
34. Guthrie R. 1996. The introduction of newborn screening for phenylketonuria. A personal history. Eur J Pediatr 155 (Suppl 1):S4, S5.
35. Guthrie R, Susi A. 1963. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338-343.
36. Guthrie R, Whitney S. 1964. Phenylketonuria. Detection in the newborn infant as a routine hospital procedure. U.S. Department of Health, Education, and Welfare, Children's Bureau.
37. Hanley WB, Linsao L, Davidson W, et al. 1970. Malnutrition with early treatment of phenylketonuria. Pediatr Res 4:318-327.
38. Heldt K, Schwahn B, Marquardt I, et al. 2005. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification. Mol Genet Metab 84:313-316.
39. Holt KS. 1963. Difficulties and dangers in the management of phenylketonuria. Acta Paediatr 52:417-423.
40. Howell RR. 2006. We need expanded newborn screening. Pediatrics 117:1800-1805.
41. Jervis GA. 1939. The genetics of phenylpyruvic oligophrenia (a contribution to the study of the influence of heredity on mental defect). J Ment Sci 85:719-762.
42. Kaplan P, Mazur A, Field M, et al. 1991. Intellectual outcome in children with maple syrup urine disease. J Pediatr 119(1, Part 1):46-50.
43. Kaplan SA, Rosenberg CE. 1975. The Family in History: Lectures Given in Memory of Stephen Allen Kaplan Under the Auspices of the Department of History at the University of Pennsylvania. Philadelphia, PA: University of Pennsylvania Press.
44. Klein RZ. 1985. Infantile hypothyroidism then and now: The results of neonatal screening. Curr Problems Pediatr 15:1-58.
45. Kwon C, Farrell PM. 2000. The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med 154:714-718.
46. Levy HL. 1973. Genetic screening. Adv Hum Genet 4:1-104.
47. Levy HL. 1974. Neonatal screening for inborn errors of amino acid metabolism. Clin Endocrinol Metab 3:153-166.
48. Levy HL, Hammersen G. 1978. Newborn screening for galactosemia and other galactose metabolic defects. J Pediatr 92:871-877.
49. Levy HL, Sepe SJ, Shih VE, et al. 1977. Sepsis due to Escherichia coli in neonates with galactosemia. N Engl J Med 297:823-825.
50. Link BG, Phelan JC. 2002. McKeown and the idea that social conditions are fundamental causes of disease. Am J Clin Nutr 92:722-725.
51. Lloyd G, editor. 1978. Hippocratic Writings. Middlesex, England: Penguin Books.
52. Mackenzie DY, Woolf LI. 1959. Maple syrup urine disease; an inborn error of the metabolism of valine, leucine, and isoleucine associated with gross mental deficiency. Br Med J 30(5114):90, 91.
53. Marsden D, Levy H. 2006. Classification of PKU. In: Blau N, editor. PKU and BH4: Advances in Phenylketouria and Tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft. pp 92-103.
54. McKeown T. 1976. The modern rise of population. London: Edward Arnold.
55. McKinlay JB, McKinlay SM. 1977. The questionable contribution of medical measures to the decline of mortality in the United States in the twentieth century. Milbank Mem Fund Q Health Soc 55:405-428.
56. Meckel R. 1990. Save the babies: american public health reform and the prevention of infant mortality. Baltimore: Johns Hopkins University Press.
57. Mendilaharzu H, Gregory T, Gardner LI. 1973. latrogenic Cushing's disease in a boy after misdiagnosis of salt-losing virilizing adrenal hyperplasia: impaired metyrapone response with failure of catch-up growth. J Pediatr 83:69-76.
58. Menkes JH. 1959. Maple syrup disease: Isolation and identification of organic acids in the urine. Pediatrics 23:348-353.
59. Menkes JH, Hurst PL, Craig JM. 1954. A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics 14:462-467.
60. Moncrieff A, Wilkinson RH. 1961. Further experiences in the treatment of phenylketonuria. Br Med J 5228:763-767.
61. National Newborn Screening and Genetics Resource Center. 2003. National Newborn Screening Report-2000. Austin, TX: NNS-GRC.
62. Naylor EW, Guthrie R. 1978. Newborn screening for maple syrup urine disease (branched-chain ketoaciduria). Pediatrics 61:262-266.
63. Nelson CD, Waggoner DD, Donnell GN, et al. 1991. Verbal dyspraxia in treated galactosemia. Pediatrics 88:346-350.
64. Online Mendelian Inheritance in Man (Galactosemia). 2006. Johns Hopkins University.
65. Pang S, Shook MK. 1997. Current status of neonatal screening for congenital adrenal hyperplasia. Curr Opin Pediatr 9:419-423.
66. Paul D. 2000. A double-edged sword. Nature 405(6786):515.
67. Pauling L, Itano HA, Singer SJ, et al. 1949. Sickle cell anemia a molecular disease. Science 110: 543-548.
68. Pearson HA. 1989. Neonatal testing for sickle cell diseases-a historical and personal review. Pediatrics 83(5, Part 2):815-818.
69. President's Panel on Mental Retardation. 1963. Mental Retardation: A National Plan for a National Problem. Washington, DC: US Department of Health, Education, and Welfare/GPO.
70. Raiti S, Newns GH. 1971. Cretinism: early diagnosis and its relation to mental prognosis. Arch Dis Child 46:692-694.
71. Rothenberg M, Sills E. 1968. Iatrogenesis: the PKU anxiety syndrome. J Am Acad Child Psychiatry 7(4):689-692.
72. Rothman DJ. 1997. Beginnings count: the technological imperative in american health care. New York: Oxford University Press.
73. Rouse BM. 1966. Phenylalanine deficiency syndrome. J Pediatr 69:246-249.
74. Royston N, Parry T. 1962. Megaloblastic anaemia complicating dietary treatment of phenylketouria in infancy. Arch Dis Child 37:430-435.
75. Schon R, Thalhammer O. 1977. False-postive galactomsaemia screening. Lancet 1(8001):43.
76. Schweitzer S. 1995. Newborn mass screening for galactosemia. Eur J Pediatr 154(7 Suppl 2): S37-S39.
77. Scriver CR. 1995. Whatever happened to PKU? Clin Biochem 28:137-144.
78. Shih VE, Levy HL, Karolkewicz V, et al. 1971. Galactosemia screening of newborns in Massachusetts. N Engl J Med 284:753-757.
79. Shorter E. 2000. The Kennedy family and the story of mental retardation. Philadelphia: Temple University Press.
80. Snyderman SE. 1976. Branched chain ketoaciduria (maple syrup urine disease). Clin Perinatol 3:41-52.
81. Starr P. 1983. The social transformation of american medicine: the rise of a sovereign profession and the making of a vast industry. New-York: Basic Books.
82. Szreter S. 2002. Rethinking McKeown: the relationship between public health and social change. Am J Clin Nutr 92:722-725.
83. Tarini BA, Christakis DA, Welch HG. 2006. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 118:448-456.
84. Thomason MJ, Lord J, Bain MD, et al. 1998. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. J Public Health Med 20:331-343.
85. Tornqvist K, Tornqvist H. 1996. Corneal deepithelialization caused by acute deficiency of isoleucine during treatment of a patient with maple syrup urine disease. Acta Ophthalmol Scand Suppl 219:48, 49.
86. Trent JW. 1994. Inventing the feeble mind: a history of mental retardation in the United States. Berkeley: University of California Press.
87. Tymstra T. 1986. False positive results in screening tests: experiences of parents of children screened for congenital hypothyroidism. Fam Pract 3:92-96.
88. Virdis R. 2005. Historical milestones in endocrinology. J Endocrinol Invest 28:944-948.
89. Waggoner DD, Buist NR, Donell GN. 1990. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 13:802-818.
90. Wailoo K. 1997. Drawing blood: technology and disease identity in twentieth-century America. Baltimore: Johns Hopkins University Press.
91. Waisbren SE, Norman TR, Schnell RR, et al. 1983. Speech and language deficits in early-treated children with galactosemia. J Pediatr 102:75-77.
92. Waisman H. 1966. Some newer inborn errors of metabolism. Pediatri Clin North Am 13:469-501.
93. Westall RG. 1963. Dietary treatment of a child with maple syrup urine disease (Branched-Chain Ketoaciduna). Arch Dis Child 38:485-491.
94. Westall RG, Dancis J, Miller S. 1957. Maple syrup urine disease. Am J Dis Child 94:571, 572.
95. WHO. 1968. Screening for inborn errors of metabolism. Report of a World Health Organization (WHO) Scientific Group. World Health Organ Tech Rep Ser 401:1-57.
96. Wilkins L, Lewis RA, Klein R, et al. 1950. The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp 86:249-252.
97. Wilson KM, Clayton BE. 1962. Importance of choline during growth, with particular reference to synthetic diets in phenylketonuria. Arch Dis Child 37:565-577.
98. Woolf LI, Griffiths R, Moncrieff A. 1955. Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J 4905:57-64.